Olezarsen for Hypertriglyceridemia: A New Therapy Update with Systematic Review and Meta-Analysis.

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Genetics

Background:

• Hypertriglyceridemia is a prevalent lipid disorder associated with increased cardiovascular disease risk.
• Elevated triglycerides pose a significant global health burden.
• Apolipoprotein C-III plays a key role in triglyceride metabolism.

Purpose of the Study:

• To evaluate the efficacy and safety of olezarsen in managing hypertriglyceridemia.
• To synthesize evidence from randomized controlled trials on olezarsen's lipid-lowering effects.
• To inform clinical decision-making regarding olezarsen as a therapeutic option.

Main Methods:

• A meta-analysis of eight randomized controlled trials comparing olezarsen to usual care.
• Literature search conducted across major databases.
• Data extraction and bias assessment using RoB 2.0 and GRADE framework; meta-analysis performed using RevMan 5.4.1 with random effects models.

Main Results:

• Olezarsen significantly reduced triglycerides (MD -58.57) and apolipoprotein C-III (MD -69.81).
• Improvements observed in apolipoprotein B, non-HDL cholesterol, and achievement of triglyceride targets.
• No increase in overall or serious adverse events, but higher rates of injection-site reactions, liver enzyme elevations, and discontinuation with olezarsen.

Conclusions:

• Olezarsen demonstrates significant efficacy in improving triglyceride levels and atherogenic lipid parameters in hypertriglyceridemia.
• The therapy exhibits a generally favorable safety profile, positioning it as a promising treatment option.
• Monitoring for liver enzymes and injection-site reactions is recommended when using olezarsen.